News

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.

Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

NVST vs. ABT: Which Stock Is the Better Value Option?

FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.

MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.

BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.

Worried about a pullback? This Dividend King pairs a 54-year streak with catalysts that could provide income even if the market crashes.

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.

The market's valuation reflects a wide breadth of potential outcomes for the company, exposing shareholders to the full magnitude of that underlying risk.

While Medtronic has outperformed relative to the Dow over the past three months, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better-

The benefit of whole milk-based baby formula is that it more closely mirrors the fat blend found in breast milk than powdered baby formula.

Despite Abbott Laboratories' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Abbott Laboratories (NYSE:ABT) launched Similac 360 Total Care Made With Whole Milk, a commercially sterile ready-to-feed liquid infant formula made with whole milk in the U.S. The product is the first of its kind in the U.S. market to combine whole milk with a ready-to-feed liquid format. The formula uses whole milk and a blend of human milk oligosaccharides to more closely mirror key elements of breast milk. The launch expands Abbott's infant nutrition portfolio and targets parents seeking...

Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.

Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk.

GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

With Amulet 360, Abbott aims to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to lower stroke risk.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...

Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.

Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.